Amylyx Pulls ALS Drug From US Market After Study Shows No Benefit
Amylyx Pharmaceuticals announced Thursday that it is voluntarily halting sales in the U.S. and Canada of Relyvrio, a drug contentiously approved by the FDA for patients with ALS, also known as Lou Gehrig’s disease. A recent clinical trial showed the medicine failed to extend life or improve symptoms.
Source: kffhealthnews.org